natgillin/translations-raw huggingface dataset:
The safety and efficacy of the 80 mg and 125 mg capsules have not been demonstrated in children less than 12 years of age. 
Varnost in učinkovitost 80 mg in 125 mg kapsul pri otrocih, mlajših od 12 let, nista bili dokazani.
Discard all the unused water remaining in the mixing cup. 
Vso vodo, ki je preostala v čaši za mešanje, zavržite.
The oral suspension may be taken with or without food. 
Bolniki lahko peroralno suspenzijo vzamejo s hrano ali brez nje.
The effect of aprepitant on the plasma concentrations of intravenously administered CYP3A4 substrates is expected to be smaller. 
Pričakuje se manjši vpliv aprepitanta na plazemske koncentracije intravensko uporabljenih substratov za CYP3A4.
If the child could not take the whole dose, call the child's healthcare provider. 
Če otrok ne more zaužiti celotnega odmerka, se posvetujte z otrokovim zdravnikom.
Aprepitant regimen (N= 433) 
Aprepitant (N = 433)
Additionally, no significant nausea in the overall period (0 to 120 hours post-chemotherapy) was evaluated as an exploratory endpoint, and in the acute and delayed phases as a post-hoc analysis. 
Poleg tega je bil eksploratorni opazovani dogodek opredeljen kot brez pomembne navzee v celotnem obdobju (0 do 120 ur po kemoterapiji) ter v post-hoc analizi akutne in zapoznele faze.
Complete response: No emesis and no use of rescue Difference (%) calculated as Aprepitant 40 mg minus Ondansetron 4 mg Difference (%) and 95 % C.I. 
Popoln odziv: Brez bruhanja in brez rešilnega zdravljenja Razlika (%) izračunana kot aprepitant 40 mg minus ondansetron 4 mg Razlika (%) in 95-odstotni IZ izračunan z uporabo stratificirane Miettinen-Nurminen metode in Cochran-Mantel-Haeszel mer
Hepatic impairment: Mild hepatic impairment (Child-Pugh class A) does not affect the pharmacokinetics of aprepitant to a clinically relevant extent. 
Okvara jeter: Blaga okvara jeter (razred A po Child-Pugh-ovi klasifikaciji) na farmakokinetiko aprepitanta ne vpliva v tolikšni meri, da bi bilo to klinično pomembno.
Following a single 165 mg aprepitant dose, a transient moderate increase for two days possibly followed by a mild decrease in exposure of immunosuppressants metabolised by CYP3A4 (e.g., cyclosporine, tacrolimus, everolimus and sirolimus) is expected. 
Po enkratnem 165 mg odmerku aprepitanta dva dni pričakujemo prehodno zmerno povečanje, nato pa morda blago zmanjšanje izpostavljenosti imunosupresivom, ki se presnavljajo s CYP3A4 (npr. ciklosporin, takrolimus, everolimus in sirolimus).
- This medicine has been prescribed for you or the child only. 
- Zdravilo je bilo predpisano vam ali vašemu otroku osebno in ga ne smete dajati drugim.
Concomitant administration of EMEND with herbal preparations containing St. John's Wort (Hypericum perforatum) is not recommended. 
Sočasno uporabo zdravila EMEND in pripravkov rastlinskega izvora, ki vsebujejo šentjanževko (Hypericum perforatum), odsvetujemo.
- The other ingredients are: sucrose, microcrystalline cellulose (E 460), hydroxypropylcellulose 
- Druge sestavine zdravila so: saharoza, mikrokristalna celuloza (E 460), hidroksipropilceluloza
For CYP2C9 and CYP3A4 substrates the induction is transient with a maximum effect reached after 3-5 days. 
Za substrate CYP2C9 in CYP3A4 je indukcija prehodna, največji učinek pa je dosežen v 3-5 dneh.
EMEND causes a transient mild induction of CYP2C9, CYP3A4 and glucuronidation approximately one week after treatment. 
Zdravilo EMEND povzroči prehodno blago indukcijo CYP2C9, CYP3A4 in glukuronidacije približno en teden po zdravljenju.
There were no margins to clinically relevant exposure. 
Meje za klinično pomembno izpostavljenost ni bilo.
Pre-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. 
Predklinični podatki na osnovi običajnih študij toksičnosti pri enkratnem in ponavljajočih se odmerkih, genotoksičnosti, kancerogenega potenciala, vpliva na sposobnost razmnoževanja in razvoja ne kažejo posebnega tveganja za človeka.
Day 1: - Give this medicine one hour before the start of the chemotherapy session. 
1. dan: - Zdravilo dajte otroku eno uro pred začetkom kemoterapije.
The safety and efficacy of EMEND 40 mg in children and adolescents below 18 years of age has not yet been established. 
Varnost in učinkovitost zdravila EMEND 40 mg pri otrocih in mladostnikih pod 18 let nista bili dokazani.
Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 to 4. 
Deksametazon morajo bolniki dobiti 1. dan 30 minut pred kemoterapijo, od 2. do 4. dne pa zjutraj.
If the dose is not administered immediately after measuring, store filled oral dispenser(s) in the refrigerator between 2°C-8°C for up to 72 hours prior to use. 
Če se odmerka ne uporabi takoj po pripravi, shranjujte napolnjen(e) odmernik(e) v hladilniku med 2 °C in 8 °C do 72 ur pred uporabo.
For CYP2C9 and CYP3A4 substrates, the induction is transient with a maximum effect reached 3-5 days after end of the EMEND 3-day treatment. 
Za substrate CYP2C9 in CYP3A4 je indukcija prehodna, največji učinek pa je dosežen v 3-5 dneh po koncu 3-dnevnega zdravljenja z zdravilom EMEND.
An analysis of efficacy in subpopulations in Cycle 1 demonstrated that, regardless of age category, gender, use of dexamethasone for antiemetic prophylaxis, and emetogenicity of chemotherapy, the aprepitant regimen provided better control than the control regimen with respect to the complete response endpoints. 
Analiza učinkovitosti v podpopulacijah v 1. ciklusu je pokazala, da so pri shemi z aprepitantom bolje obvladani opazovani dogodki popolnega odziva kot pri kontrolni shemi, ne glede na starostno kategorijo, spol, uporabo deksametazona za antiemetično profilakso ter emetogenost kemoterapije.
It is not known whether aprepitant is excreted in human milk; therefore, breast-feeding is not recommended during treatment with EMEND. 
Ni znano, ali se aprepitant izloča v mleko doječih mater, zato dojenje med zdravljenjem z zdravilom EMEND odsvetujemo.
If you have any further questions on the use of this medicine, ask the doctor or pharmacist. 
Če imate dodatna vprašanja o uporabi tega zdravila, se posvetujte z zdravnikom ali farmacevtom.
- Choose the oral dispenser based on dose: - Use 1 mL oral dispenser if dose is 1 mL or less. 
- Odmernik izberite glede na velikost odmerka: - Če je odmerek 1 ml ali manjši, uporabite 1-ml odmernik.
The effect is maintained for a few days, thereafter slowly declines and is clinically insignificant within 14 days after end of EMEND treatment. 
Učinek traja nekaj dni, potem pa počasi upada in je klinično nepomemben v 14 dneh po koncu zdravljenja z zdravilom EMEND.
In clinical interaction studies, aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg on Days 2 and 3, did not have clinically important effects on the pharmacokinetics of ondansetron, granisetron, or hydrodolasetron (the active metabolite of dolasetron). 
V kliničnih študijah medsebojnega delovanja aprepitant, uporabljen po shemi 125 mg 1. dan ter 80 mg 2. in 3. dan, ni imel klinično pomembnih učinkov na farmakokinetiko ondansetrona, granisetrona ali hidrodolasetrona (aktivnega presnovka dolasetrona).
Aprepitant regimen (N= 521) 
Aprepitant (N = 521)
No vomiting 
Brez bruhanja
Contains sucrose and lactose. 
Vsebuje saharozo in laktozo.
Always give this medicine together with other medicines, to prevent nausea and vomiting. 
To zdravilo dajte vedno skupaj z drugimi zdravili za preprečevanje navzee (siljenja na bruhanje) in bruhanja.
Add the 4.6 mL of water from the oral dispenser back into the mixing cup. 
4. 4,6 ml vode iz odmernika dajte nazaj v čašo za mešanje.
The effect may be maintained for a few days, and is expected to be clinically insignificant by two weeks after the end of treatment with EMEND. 
Učinek traja nekaj dni in za pričakovati je, da bo klinično nepomemben v dveh tednih po koncu zdravljenja z zdravilom EMEND.
The dose of dexamethasone accounts for active substance interactions. 
Odmerek deksametazona upošteva medsebojno delovanje zdravilnih učinkovin.
During treatment for chemotherapy induced nausea and vomiting (CINV), the 3-day 125 mg/80 mg regimen of aprepitant is a moderate inhibitor of CYP3A4. 
Pri 3-dnevnem zdravljenju navzee in bruhanja zaradi kemoterapije (CINV; chemotherapy induced nausea and vomiting) po režimu 125 mg/80 mg je aprepitant zmerni zaviralec CYP3A4.
For information regarding pregnancy, breast-feeding and contraception, ask your doctor for advice. 
Zdravnika prosite za nasvet v zvezi z nosečnostjo, dojenjem in kontracepcijo.
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years. 
Preprečevanje navzee in bruhanja, ki spremljata zelo emetogeno ter zmerno emetogeno kemoterapijo raka pri otrocih, malčkih in dojenčkih, starih od 6 mesecev do manj kot 12 let.
As a mild inducer of CYP2C9, CYP3A4 and glucuronidation, aprepitant can decrease plasma concentrations of substrates eliminated by these routes. 
Kot blag induktor CYP2C9, CYP3A4 in glukuronidacije lahko aprepitant zniža plazemske koncentracije substratov, ki se izločajo po teh poteh.
The powder for oral suspension contains sucrose and lactose. 
Prašek za peroralno suspenzijo vsebuje saharozo in laktozo.
Aprepitant plasma concentrations achieved with the 3-day regimen of EMEND are predicted to provide greater than 95 % occupancy of brain NK1 receptors. 
Predvidevajo, da plazemske koncentracije aprepitanta, ki jih dosežemo s 3 dni trajajočim zdravljenjem z zdravilom EMEND, zagotavljajo več kot 95-odstotno zasedenost možganskih receptorjev NK1.
The mean peak plasma concentration (Cmax) of aprepitant occurred at approximately 4 hours (tmax). 
Povprečna najvišja plazemska koncentracija (Cmax) aprepitanta je bila dosežena po približno 4 urah (tmax).
The terminal half-life is approximately 9 hours after administration of a single 40 mg dose. 
Končni razpolovni čas po zaužitju enkratnega 40 mg odmerka je znašal približno 9 ur.
If a doctor has told you that the child has an intolerance to some sugars, contact the doctor before giving this medicine to the child. 
Če vam je zdravnik povedal, da otrok ne prenaša nekaterih sladkorjev, se posvetujte z zdravnikom, preden začnete otroku dajati to zdravilo.
If the dose is not administered immediately after measuring, the filled oral dispenser can be refrigerated (between 2°C and 8°C) for up to 72 hours prior to use. 
Če odmerka ne uporabite takoj po pripravi, lahko napolnjen odmernik shranjujete v hladilniku (med 2 °C in 8 °C) do 72 ur pred uporabo.
Infection and infestations candidiasis, staphylococcal infection rare 
Infekcijske in parazitske bolezni kandidoza, okužba s stafilokoki redki
No emesis (no emetic episodes regardless of use of rescue therapy) Overall (0-120 hours) 
Brez bruhanja (brez bruhanja ne glede na rešilno zdravljenje) Skupaj (0-120 ur)
No dose adjustment for EMEND is necessary in elderly patients. 
Odmerka zdravila EMEND pri starejših ni treba prilagoditi.
EMEND is given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 antagonist. 
Zdravilo EMEND se daje 3 dni po shemi zdravljenja, ki vključuje kortikosteroid in antagonist 5-HT3.
2-day treatment pack containing: 2 x 80 mg hard capsule 
Pakiranje za 2-dnevno zdravljenje vsebuje: 2 x 80 mg trda kapsula
Because the effect of EMEND on the pharmacokinetics of orally administered CYP3A4 substrates is greater than the effect of EMEND on the pharmacokinetics of intravenously administered CYP3A4 substrates, an interaction with orally administered chemotherapeutic medicinal products metabolised primarily or partly by CYP3A4 (e.g., etoposide, vinorelbine) cannot be excluded. 
Ker je učinek zdravila EMEND na farmakokinetiko substratov za CYP3A4, če so dani peroralno, večji kot če so dani intravensko, interakcije s peroralno danimi kemoterapevtiki, ki se primarno ali delno presnavljajo s CYP3A4 (npr. etopozid, vinorelbin), ne moremo izključiti.
Please talk to the doctor or pharmacist if you or the child is taking any of the following medicines: 
Obvestite zdravnika ali farmacevta, če vi ali otrok jemljete katero koli od naslednjih zdravil:
However, in a 9 month study in dogs, no organ weight changes nor gross or histomorphologic findings were present in male reproductive organs at systemic exposures 35-fold above the therapeutic exposure in humans at 40 mg. 
Vendar pa v 9-mesečni študiji pri psih pri sistemski izpostavljenosti, ki je 35-krat presegala terapevtsko izpostavljenost človeka pri 40 mg odmerku, ni bilo sprememb v teži organov niti histomorfoloških ali makroskopskih sprememb v moških reproduktivnih organih.
Caution is advised when warfarin, acenocoumarol, tolbutamide, phenytoin or other active substances that are known to be metabolised by CYP2C9 are administered during this time period. 
V tem obdobju svetujemo previdnost pri dajanju varfarina, acenokumarola, tolbutamida, fenitoina in drugih zdravilnih učinkovin, ki se presnavljajo s CYP2C9.
Tell your doctor if you are taking these medicines since your treatment must be modified before you start taking EMEND. 
Če jemljete katerega od teh zdravil, to povejte zdravniku, saj bo treba vaše zdravljenje pred začetkom jemanja zdravila EMEND spremeniti.
EMEND 40 mg hard capsules are supplied in the following pack sizes: - Aluminium blister containing one 40 mg capsule - 5 Aluminium blisters each containing one 40 mg capsule 
EMEND 40 mg trde kapsule so na voljo v naslednjih pakiranjih: - ena 40 mg kapsula v aluminijastem pretisnem omotu; - 5 aluminijastih pretisnih omotov, ki vsebujejo po eno 40 mg kapsulo.
The dose of dexamethasone in chemotherapy induced nausea and vomiting clinical trials was chosen to account for active substance interactions (see section 4.2). 
Odmerek deksametazona je bil v kliničnih študijah navzee in bruhanja zaradi kemoterapije določen z upoštevanjem medsebojnega delovanja zdravilnih učinkovin (glejte poglavje 4.2).
If you forget to take EMEND If you or the child has missed a dose, contact your doctor for advice. 
Če ste pozabili vzeti zdravilo EMEND Če ste vi ali otrok pozabili vzeti odmerek, se posvetujte z zdravnikom.
Skin and subcutaneous tissue disorders pruritus, rash, urticaria, Stevens-Johnson syndrome/toxic epidermal necrolysis not known 
Bolezni kože in podkožja srbenje, izpuščaj, urtikarija, Stevens-Johnsonov sindrom/toksična epidermalna nekroliza neznana
Stevens-Johnson syndrome or toxic epidermal necrolysis (rare severe skin reactions) - euphoria (feeling of extreme happiness), feeling confused - bacterial infection, fungal infection - severe constipation, stomach ulcer, inflamed small intestine and colon, sores in the mouth, 
Stevens-Johnsonov sindrom ali toksična epidermalna nekroliza (redke, hude kožne reakcije) - evforija (občutek pretiranega veselja), občutek zmedenosti - bakterijska okužba, glivna okužba - hudo zaprtje, razjeda na želodcu, vnetje tankega in debelega črevesa, razjede v ustih,
Data are lacking regarding effects of CYP2C8 and CYP2C19. 
Glede učinkov CYP2C8 in CYP2C19 ni podatkov.
Co-administration with pimozide, terfenadine, astemizole or cisapride (see section 4.5). 
Sočasna uporaba s pimozidom, terfenadinom, z astemizolom ali s cisapridom (glejte poglavje 4.5).
EMEND must not be used concurrently with pimozide, terfenadine, astemizole, or cisapride (see section 4.3). 
Zdravila EMEND se ne sme uporabljati skupaj s pimozidom, terfenadinom, z astemizolom ali s cisapridom (glejte poglavje 4.3).
If you forget to take EMEND If you have missed a dose, contact your doctor for advice. 
Če ste pozabili vzeti zdravilo EMEND Če ste pozabili vzeti odmerek, se posvetujte z zdravnikom.
Inhibition of cytochrome P450 isoenzyme 3A4 (CYP3A4) by aprepitant could result in elevated plasma concentrations of these active substances, potentially causing serious adverse reactions (see section 4.5). 
Aprepitant zavira delovanje izoencima 3A4 citokroma P450 (CYP3A4), zaradi česar bi se lahko zvišale plazemske koncentracije teh zdravilnih učinkovin, kar bi lahko povzročilo resne neželene reakcije (glejte poglavje 4.5).
As a mild inducer of CYP2C9, CYP3A4 and glucuronidation, aprepitant can decrease plasma concentrations of substrates eliminated by these routes within two weeks following initiation of treatment. 
Kot blag induktor CYP2C9, CYP3A4 in glukuronidacije lahko aprepitant zniža plazemske koncentracije substratov, ki se izločajo po teh poteh, v dveh tednih po uvedbi zdravljenja.
Oral administration of the capsule with an approximately 800 Kcal standard breakfast resulted in an up to 40 % increase in AUC of aprepitant. 
Po peroralnem zaužitju kapsule skupaj z običajnim zajtrkom z 800 kcal se je AUC aprepitanta povečal za največ 40 %.
Take one EMEND 125 mg capsule by mouth 1-hour BEFORE you start your chemotherapy treatment. 
Eno EMEND 125 mg kapsulo zaužijte eno uro PRED začetkom kemoterapije.
Aprepitant displays non-linear pharmacokinetics. 
Farmakokinetika aprepitanta ni linearna.
EMEND powder for oral suspension contains sucrose and lactose. 
Prašek za peroralno suspenzijo EMEND vsebuje saharozo in laktozo.
C]-fosaprepitant, a prodrug for aprepitant, indicating a substantial presence of metabolites in the plasma. 
C-fosaprepitanta, predzdravila aprepitanta, približno 19 % radioaktivnosti v plazmi prispeval aprepitant, kar kaže na znatno prisotnost presnovkov v plazmi.
Parents and caregivers: Always give this medicine to the child exactly as the doctor, pharmacist or nurse has told you. 
Starši in skrbniki: Pri dajanju tega zdravila otroku natančno upoštevajte navodila zdravnika, farmacevta ali medicinske sestre.
During the 3-day CINV regimen, a transient moderate increase followed by a mild decrease in exposure of immunosuppressants metabolised by CYP3A4 (e.g., cyclosporine, tacrolimus, everolimus and sirolimus) is expected. 
Med 3-dnevnim režimom preprečevanja CINV pričakujemo prehodno zmerno povečanje, nato pa blago zmanjšanje izpostavljenosti imunosupresivom, ki se presnavljajo s CYP3A4 (npr. ciklosporin, takrolimus, everolimus in sirolimus).
Common: may affect up to 1 in 10 people - constipation or indigestion - headache - feeling tired - loss of appetite - hiccups - increased amount of liver enzymes in the blood (shown in tests). 
Pogosti: pojavijo se lahko pri do 1 od 10 bolnikov - zaprtje ali prebavne motnje - glavobol - utrujenost - izguba apetita - kolcanje - zvišana vrednost jetrnih encimov v krvi (pokaže se na preiskavah krvi).
The recommended oral dose of EMEND is one 165 mg capsule on the first day of your chemotherapy treatment cycle. 
Priporočeni peroralni odmerek zdravila EMEND je ena 165 mg kapsula 1. dan ciklusa kemoterapije.
Aprepitant regimen n/m (%) 
Shema z aprepitantom n/m (%)
The effect is maintained for a few days, thereafter slowly declines and is clinically insignificant by two weeks after end of EMEND treatment. 
Učinek traja nekaj dni, potem pa počasi upada in je klinično nepomemben v dveh tednih po koncu zdravljenja z zdravilom EMEND.
This is because EMEND can affect how other medicines work, during and after treatment with EMEND. 
Zdravilo EMEND namreč lahko vpliva na delovanje drugih zdravil tako med zdravljenjem z zdravilom EMEND kot po njem.
Each pack of EMEND contains a sachet with the powder for oral suspension, a 1 ml and a 5 ml oral dispenser, one cap and one mixing cup. 
Vsako pakiranje zdravila EMEND vsebuje vrečko s praškom za peroralno suspenzijo, 1-ml in 5-ml odmernik, eno zaporko in eno čašo za mešanje.
If you are not sure, talk to the doctor, pharmacist or nurse before giving this medicine. 
Če ste negotovi, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, preden otroku daste to zdravilo.
Administration of body surface area adjusted doses to patients 6 months to less than 12 years achieved a mean AUC0-48hr above 4 µg/mL with a mean Cmax above 0.5 µg/mL occurring at approximately 3 hours. 
Med uporabo na telesno površino prilagojenih odmerkov pri bolnikih, starih od 6 mesecev do manj kot 12 let, je bila dosežena povprečna AUC0-48h nad 4 µg/ml, povprečna Cmax nad 0,5 µg/ml pa se je pojavila po približno 3 urah.
As part of a 3-day regimen, dosing of aprepitant powder for oral suspension (3/2/2-mg/kg) in patients aged 6 months to less than12 years achieved an AUC0-24hr above 17 µg•hr/mL on Day 1 with concentrations (Cmin) at the end of Days 2 and 3 above 0.1 µg/mL in a majority of patients. 
V okviru 3-dnevne sheme je bila pri uporabi aprepitanta v prašku za peroralno suspenzijo (3/2/2 mg/kg) pri bolnikih, starih od 6 mesecev do manj kot 12 let, pri večini bolnikov dosežena AUC0-24h nad 17 µg•h/ml 1. dan, koncentracije (Cmin) ob koncu 2. in 3. dne pa so bile nad 0,1 µg/ml.
Microcrystalline cellulose (E 460) Hydroxypropylcellulose (E 463) Sodium laurilsulfate 
Vsebina kapsule saharoza mikrokristalna celuloza (E 460) hidroksipropilceluloza (E 463) natrijev lavrilsulfat
AST increased, blood alkaline phosphatase increased uncommon red blood cells urine positive, blood sodium decreased, weight decreased, neutrophil count decreased, glucose urine present, urine output increased rare 
pogosti zvišanje vrednosti AST, zvišanje vrednosti alkalne fosfataze v krvi občasni prisotnost rdečih krvnih celic v urinu, znižane vrednosti natrija v krvi, zmanjšanje telesne mase, zmanjšano število nevtrofilcev, prisotnost glukoze v urinu, povečano izločanje urina redki
Co-administration of EMEND with active substances that are known to be metabolized by CYP2C9 (e.g., phenytoin, warfarin), may result in lower plasma concentrations of these active substances. 
Pri sočasnem jemanju zdravila EMEND in zdravilnih učinkovin, za katere je znano, da se presnavljajo s CYP2C9 (npr. fenitoin, varfarin), se lahko zmanjša plazemska koncentracija teh zdravilnih učinkovin.
Aprepitant is a substrate, a moderate inhibitor, and an inducer of CYP3A4. 
Aprepitant je substrat, zmerni zaviralec in induktor CYP3A4.
During treatment, the single 40 mg dose of aprepitant recommended for PONV results in a weak inhibition of CYP3A4. 
Pri enkratnem 40 mg odmerku, ki je priporočen za uporabo pri PONV, je zaviranje CYP3A4 šibko.
Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy in adults. 
Preprečevanje akutne in zapoznele navzee in bruhanja, povezanih z zelo emetogeno kemoterapijo raka s cisplatinom pri odraslih.
Concomitant administration of EMEND with active substances that strongly induce CYP3A4 activity (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital) should be avoided as the combination results in reductions of the plasma concentrations of aprepitant that may result in decreased efficacy of EMEND. 
Sočasnemu dajanju zdravila EMEND in zdravilnih učinkovin, ki močno inducirajo aktivnost CYP3A4 (npr. rifampicin, fenitoin, karbamazepin, fenobarbital), se je treba izogibati, saj se pri kombiniranju zmanjšajo plazemske koncentracije aprepitanta, zaradi česar se lahko zmanjša učinkovitost zdravila EMEND.
everolimus - alfentanil, fentanyl - for pain - quinidine - for irregular heart beat - medicines for cancer - such as irinotecan, etoposide, vinorelbine, ifosfamide - medicines containing ‘ergot alkaloid derivatives' - such as ergotamine and diergotamine - for migraines - medicines that thin the blood - such as warfarin, acenocoumarol. 
everolimus - alfentanil, fentanil - za zdravljenje bolečin - kinidin - za zdravljenje nerednega bitja srca - zdravila za zdravljenje raka - na primer irinotekan, etopozid, vinorelbin, ifosfamid - zdravila, ki vsebujejo derivate ergot alkaloidov, na primer ergotamin in diergotamin - za zdravljenje migrene - zdravila za redčenje krvi - na primer varfarin, acenokumarol.
EMEND may have minor influence on the ability to drive, cycle and use machines. 
Zdravilo EMEND ima lahko blag vpliv na sposobnost vožnje, kolesarjenja in upravljanja s stroji.
Do not take EMEND: - if you are allergic to aprepitant or any of the other ingredients of this medicine (listed in section 6). 
Ne jemljite zdravila EMEND: - če ste alergični na aprepitant ali katero koli sestavino tega zdravila (navedeno v poglavju 6).